Low Levels of High-density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients: A Post-hoc Analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug...

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2013 Aug 27

PMID 23973693

Citations 32

Authors

Subroto Acharjee

William E Boden

Pamela M Hartigan

Koon K Teo

David J Maron

Steven P Sedlis

William Kostuk

John A Spertus

Marcin Dada

Bernard R Chaitman

G B John Mancini

William S Weintraub

Affiliations

Soon will be listed here.

Abstract

Objectives: This study sought to assess the independent effect of high-density lipoprotein-cholesterol (HDL-C) level on cardiovascular risk in patients with stable ischemic heart disease (SIHD) who were receiving optimal medical therapy (OMT).

Background: Although low HDL-C level is a powerful and independent predictor of cardiovascular risk, recent data suggest that this may not apply when low-density lipoprotein-cholesterol (LDL-C) is reduced to optimal levels using intensive statin therapy.

Methods: We performed a post-hoc analysis in 2,193 men and women with SIHD from the COURAGE trial. The primary outcome measure was the composite of death from any cause or nonfatal myocardial infarction (MI). The independent association between HDL-C levels measured after 6 months on OMT and the rate of cardiovascular events after 4 years was assessed. Similar analyses were performed separately in subjects with LDL-C levels below 70 mg/dl (1.8 mmol/l).

Results: In the overall population, the rate of death/MI was 33% lower in the highest HDL-C quartile as compared with the lowest quartile, with quartile of HDL-C being a significant, independent predictor of death/MI (p = 0.05), but with no interaction for LDL-C category (p = 0.40). Among subjects with LDL-C levels <70 mg/dl, those in the highest quintile of HDL-C had a 65% relative risk reduction in death or MI as compared with the lowest quintile, with HDL-C quintile demonstrating a significant, inverse predictive effect (p = 0.02).

Conclusions: In this post-hoc analysis, patients with SIHD continued to experience incremental cardiovascular risk associated with low HDL-C levels despite OMT during long-term follow-up. This relationship persisted and appeared more prominent even when LDL-C was reduced to optimal levels with intensive dyslipidemic therapy. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657).

Citing Articles

Elevated atherogenic index of plasma is associated with increased cardiorenal syndrome prevalence: a cross-sectional study.

Xu S, Hu J, Ouyang Z, Yuan M, Zheng Y, Liu X Ren Fail. 2025; 47(1):2472037.

PMID: 40025821 PMC: 11878164. DOI: 10.1080/0886022X.2025.2472037.

Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program.

Bertolin-Boronat C, Merenciano-Gonzalez H, Marcos-Garces V, Martinez-Mas M, Climent Alberola J, Perez N Rev Cardiovasc Med. 2025; 26(1):25399.

PMID: 39867202 PMC: 11759968. DOI: 10.31083/RCM25399.

High-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Risk Assessment: Exploring and Explaining the "U"-Shaped Curve.

Razavi A, Mehta A, Jain V, Patel P, Liu C, Patel N Curr Cardiol Rep. 2023; 25(12):1725-1733.

PMID: 37971636 PMC: 10898346. DOI: 10.1007/s11886-023-01987-3.

Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?.

Razavi A, Jain V, Grandhi G, Patel P, Karagiannis A, Patel N J Clin Endocrinol Metab. 2023; 109(2):321-332.

PMID: 37437107 PMC: 11032254. DOI: 10.1210/clinem/dgad406.

In Mild and Moderate Acute Ischemic Stroke, Increased Lipid Peroxidation and Lowered Antioxidant Defenses Are Strongly Associated with Disabilities and Final Stroke Core Volume.

Maes M, Brinholi F, Michelin A, Matsumoto A, de Oliveira Semeao L, Almulla A Antioxidants (Basel). 2023; 12(1).

PMID: 36671047 PMC: 9854933. DOI: 10.3390/antiox12010188.

References

. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251(3):351-64. DOI: 10.1001/jama.1984.03340270029025. View

Boden W, ORourke R, Teo K, Hartigan P, Maron D, Kostuk W . Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006; 151(6):1173-9. DOI: 10.1016/j.ahj.2005.08.015. View

Libby P . The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005; 46(7):1225-8. DOI: 10.1016/j.jacc.2005.07.006. View

deGoma E, Rader D . High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein?. J Am Coll Cardiol. 2012; 60(6):517-20. DOI: 10.1016/j.jacc.2012.03.058. View

LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

Maron D, Boden W, ORourke R, Hartigan P, Calfas K, Mancini G . Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010; 55(13):1348-58. DOI: 10.1016/j.jacc.2009.10.062. View

10.

Barter P, Gotto A, LaRosa J, Maroni J, Szarek M, Grundy S . HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13):1301-10. DOI: 10.1056/NEJMoa064278. View

11.

Assmann G, Schulte H, von Eckardstein A, Huang Y . High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124 Suppl:S11-20. DOI: 10.1016/0021-9150(96)05852-2. View

12.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

13.

Deedwania P, Barter P, Carmena R, Fruchart J, Grundy S, Haffner S . Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006; 368(9539):919-28. DOI: 10.1016/S0140-6736(06)69292-1. View

14.

Ridker P, Genest J, Boekholdt S, Libby P, Gotto A, Nordestgaard B . HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010; 376(9738):333-9. DOI: 10.1016/S0140-6736(10)60713-1. View

15.

Downs J, Clearfield M, Weis S, Whitney E, Shapiro D, Beere P . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279(20):1615-22. DOI: 10.1001/jama.279.20.1615. View

16.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. DOI: 10.1016/j.jacc.2004.07.001. View

17.

Gordon D, Probstfield J, Garrison R, Neaton J, CASTELLI W, Knoke J . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15. DOI: 10.1161/01.cir.79.1.8. View

18.

Schwartz G, Olsson A, Abt M, Ballantyne C, Barter P, Brumm J . Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22):2089-99. DOI: 10.1056/NEJMoa1206797. View

19.

Gordon T, CASTELLI W, Hjortland M, Kannel W, DAWBER T . High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977; 62(5):707-14. DOI: 10.1016/0002-9343(77)90874-9. View

20.

Olsson A, Schwartz G, Szarek M, Sasiela W, Ezekowitz M, Ganz P . High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005; 26(9):890-6. DOI: 10.1093/eurheartj/ehi186. View